logo
PepsiCo posts better-than-expected second quarter despite lower US sales

PepsiCo posts better-than-expected second quarter despite lower US sales

BreakingNews.ie5 days ago
PepsiCo reported better-than-expected earnings and revenue in the second quarter despite sluggish North American sales.
Sales of Frito-Lay and other snacks fell 1% in North America during the April-June period, PepsiCo said on Thursday, while beverage sales were down 2% in the region.
Advertisement
But sales rose in some other regions, including Latin America and Asia.
Revenue rose less than 1% to 22.7 billion dollars (£17 billion) in the April-June period. That was higher than the 22.3 billion dollars Wall Street forecast, according to analysts polled by FactSet.
PepsiCo's net income fell 59% to 1.3 billion dollars (£970 million). Adjusted for one-time items, PepsiCo earned 2.12 dollars per share. That was also higher than the 2.03 dollars analysts forecast.
PepsiCo shares rose more than 2% in pre-market trading on Thursday.
Advertisement
PepsiCo lowered its full-year earnings expectations in April, citing increased costs from tariffs and a pullback in consumer spending. The company reaffirmed that guidance on Thursday.
Its tariff costs have risen since then. In June, the Trump administration hiked the tariff on imported aluminium from 25% to 50%.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

European second-quarter corporate profits expected to fall 0.3%
European second-quarter corporate profits expected to fall 0.3%

Reuters

time5 minutes ago

  • Reuters

European second-quarter corporate profits expected to fall 0.3%

July 22 (Reuters) - The outlook for European corporate health has slightly improved, the latest earnings forecasts showed on Tuesday, despite continued uncertainty over global trade and the European Union preparing for counter-measures against any major U.S. tariffs. European companies are expected to report a drop of 0.3% in second-quarter earnings, on average, according to LSEG I/B/E/S data. That is slightly above the 0.7% fall analysts expected a week ago. Forecasts for Europe-wide STOXX 600 (.STOXX), opens new tab company earnings have steadily worsened since U.S. President Donald Trump announced plans for "reciprocal" tariffs in February. Analysts expected second-quarter earnings to increase 9.1% year-on-year right before the announcement, according to the data. The consensus forecast for second-quarter revenue, on the other hand, has continued to weaken, the LSEG report showed, with analysts now expecting a 3.1% fall versus a 3.0% drop last week. That would be the worst quarterly performance in more than a year. A year ago, STOXX 600 companies on average delivered a 3.0% increase in second-quarter earnings and a 0.8% drop in revenues. This earnings season will highlight how Trump's tariff threats are affecting European companies, as many of them scramble to minimise risks and prepare strategies to counter uncertainty. Italian-listed Stellantis ( opens new tab said on Monday tariffs had already cost the auto group 300 million euros ($351 million) and pharma firm AstraZeneca (AZN.L), opens new tab announced plans to spend $50 billion expanding in the U.S. by 2030. Among sectors, the earnings of STOXX 600 technology firms are expected to increase 26.5% in the second quarter, while those of consumer cyclicals - auto, retail and entertainment companies - are forecast to shrink 23.6%, the LSEG data showed. ($1 = 0.8545 euros)

IQVIA beats quarterly estimates on resilient demand for healthcare analytics
IQVIA beats quarterly estimates on resilient demand for healthcare analytics

Reuters

time6 minutes ago

  • Reuters

IQVIA beats quarterly estimates on resilient demand for healthcare analytics

July 22 (Reuters) - Contract research firm IQVIA Holdings (IQV.N), opens new tab posted second-quarter profit and revenue above Wall Street expectations on Tuesday, as demand rose for its healthcare data and analytics services, sending shares up around 8% in premarket trading. IQVIA's technology and analytics unit, which serves pharmaceutical and consumer health companies, benefited from higher drug approvals by the U.S. Food and Drug Administration. Still, the company narrowed its annual earnings forecast as drugmakers and biotech companies have been cancelling orders given to contract research firms, in response to the U.S. government's drug price negotiation program, proposed federal research budget cuts and potential tariffs. The Trump administration has been considering separate tariffs for the pharmaceutical industry, which could be as high as 200%. But analysts said that, overall, the quarterly results had "more pluses than minuses." "All-in, this print could have been worse and should clear a fairly low bar heading into the quarter," Leerink Partners analyst Michael Cherny said in a note. Quarterly sales at the technology and analytics unit was $1.63 billion, compared with estimates of $1.60 billion, according to data compiled by LSEG. IQVIA's total quarterly revenue rose 5.3% to $4.02 billion, beating analysts' average estimate of $3.96 billion. On an adjusted basis, it reported profit of $2.81 per share for the quarter ending June 30, above expectations of $2.77 per share. IQVIA now expects annual adjusted profit per share between $11.75 and $12.05, compared with $11.70 to $12.10 earlier. The Durham, North Carolina-based company also narrowed its annual revenue expectations to between $16.1 billion and $16.3 billion, from $16 billion to $16.4 billion earlier. The new forecast assumes a roughly $100 million COVID-related impact.

China's market regulator suspends antitrust investigation into DuPont China
China's market regulator suspends antitrust investigation into DuPont China

Reuters

time6 minutes ago

  • Reuters

China's market regulator suspends antitrust investigation into DuPont China

BEIJING, July 22 (Reuters) - China's market regulator said in a statement on Tuesday that it had suspended the antitrust investigation into DuPont China Group, a subsidiary of the U.S. firm DuPont (DD.N), opens new tab. The regulator launched an investigation into DuPont China in April for its alleged violation of the country's anti-monopoly law, amid a heated trade war between China and the Unites States.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store